We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Dechra Pharmaceuticals Plc | LSE:DPH | London | Ordinary Share | GB0009633180 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3,866.00 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMDPH AMENDMENT - this form replaces previous form released on 15/01/21 at 15:25 PM UK (London) time. Correction made in Section 2, (a). FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1 KEY INFORMATION (a) Full name of discloser: MELQART ASSET MANAGEMENT (UK) LTD (b) Owner or controller of interests and short positions disclosed, if different from 1(a): N/A The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Dechra Pharmaceuticals PLC Use a separate form for each offeror/offeree (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A (e) Date position held/dealing undertaken: 2024-01-12 For an opening position disclosure, state the latest practicable date prior to the disclosure (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? No If it is a cash offer or possible cash offer, state "N/A" 2 POSITIONS OF THE PERSON MAKING THE DISCLOSURE If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security. Interests and short positions in the relevant securities of the offeror or offeree to (a) which the disclosure relates following the dealing (if any) Class of relevant security: 1p ordinary Interests Short positions Number % Number % (1) Relevant securities owned and/or controlled: (2) Cash-settled derivatives: 1,887,566 1.66% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: TOTAL: 1,887,566 1.66% All interests and all short positions should be disclosed. Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions). (b) Rights to subscribe for new securities (including directors' and other employee options) Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3 DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in. The currency of all prices and other monetary amounts should be stated. (a) Purchases and sales Class of relevant Price per unit security Purchase/sale Number of securities (GBp) (b) Cash-settled derivative transactions Price per Class of relevant Product Number of reference unit security description Nature of dealing securities (GBp) e.g. opening/closing a long/short position, increasing/reducing a e.g. CFD long/short position decreasing a long 1p ordinary CFD position -38,760 3865 GBp (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Writing, Number of Option Product purchasing, securities money Class of description selling, to which Exercise paid/ relevant e.g. call varying option price per Expiry received security option etc. relates unit Type date per unit e.g. American, European etc. (ii) Exercise Class of Exercising/ relevant exercised Number of Exercise price security Product description against securities per unit e.g. call option (d) Other dealings (including subscribing for new securities) Class of Price per unit relevant (if security Nature of dealing Details applicable) e.g. subscription, conversion 4 OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none" None (b) Agreements, arrangements or understandings relating to options or derivatives Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none" None (c) Attachments Is a Supplemental Form 8 (Open Positions) attached? No Date of disclosure: 2024-01-15 Contact name: Ben Sharp Telephone number: +44 (0)20 3826 4493 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240115388349/en/
CONTACT:
Melqart Asset Management
SOURCE: Melqart Asset Management Copyright Business Wire 2024
(END) Dow Jones Newswires
January 15, 2024 10:40 ET (15:40 GMT)
1 Year Dechra Pharmaceuticals Chart |
1 Month Dechra Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions